Appili Therapeutics Inc Class A (TSE:APLI) has released an update.
Appili Therapeutics Inc. has reported significant progress in the first quarter of FY 2025, including a definitive agreement with Aditxt that promises a substantial premium for shareholders, development advancements in their drug programs, and the successful launch of their FDA-approved drug LIKMEZ™ with Saptalis Pharmaceuticals. The company has secured funding from the U.S. Air Force Academy for their biodefense vaccine candidate ATI-1701 and is in discussions with the FDA for their antiparasitic product ATI-1801.
For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.
